Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:17 PM
Ignite Modification Date: 2025-12-24 @ 11:17 PM
NCT ID: NCT03935256
Eligibility Criteria: Inclusion Criteria: * Surgically managed endometrial cancer with total or radical hysterectomy with pathology of endometrioid, serous, clear cell or carcinosarcoma histologies * Any patient for whom combination of adjuvant radiotherapy and chemotherapy is recommended following pathology review * Endometrioid type FIGO Stage I-II with high risk features AND IIIC1, IVA * Serous Carcinoma, Clear Cell Carcinoma, Carcinosarcoma Stage I-IIIC1, IVA * ECOG Performance Status 0-2 * No prior history of pelvic radiotherapy * No clinical or radiographic evidence of nodal disease or distant metastases * Ability to understand and willingness to sign a written informed consent. Exclusion Criteria: * Patients undergoing irradiation of the para-aortic node chain * Prior history of endometrial cancer * Prior local radiotherapy for a pelvic malignancy * Prior platinum or taxane based chemotherapy for any malignancy * Patients receiving any other investigational agents * Patients with a known malignancy with a disease free interval \< 6 months prior to enrollment * Uncontrolled intercurrent illness including but not limited to ongoing or active infection, severely symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that could limit compliance with study requirements * Patients enrolled on a competing investigational study.
Healthy Volunteers: False
Sex: FEMALE
Minimum Age: 18 Years
Study: NCT03935256
Study Brief:
Protocol Section: NCT03935256